Neurocrine Biosciences, Inc. has announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. 

Dr. Keswani, an accomplished physician-scientist who has more than 20 years of pharmaceutical industry experience with broad R&D expertise in multiple therapeutic areas, will lead the clinical development and medical affairs activities at Neurocrine. Dr. Keswani succeeds Eiry W. Roberts, M.D., who has served as CMO for the past seven years and who will remain with Neurocrine in a strategic advisory role.

"Sanjay brings a wealth of strategic and development expertise to our team, enhancing our capabilities as we enter an exciting and pivotal time for the company. His contributions will extend our reach beyond small molecule medicines, enabling us to explore new modalities across our therapeutic areas of focus," said Kyle W. Gano, Ph.D., Chief Executive Officer, Neurocrine Biosciences. 

"I am thrilled to be joining Neurocrine at this stage of the company's evolution. I am drawn by Neurocrine's enduring R&D commitment to developing much-needed treatments for patients using a rigorous scientific approach involving diverse modalities, including small molecule, peptide, antibody, and gene therapy," said Dr. Keswani.

Dr. Keswani has more than two decades of executive leadership experience across both large pharmaceutical companies and small biotechnology firms – and was instrumental in the development of several first-in-class and best-in-class approved medicines. Before joining Neurocrine, he was the President and CEO of ImmunoBrain, a clinical-stage biotechnology firm focused on developing therapeutics that leverage endogenous neuroimmune communication to promote brain repair in patients with neurodegenerative diseases. 

He will continue to serve on ImmunoBrain's board of directors. Before that, he was Senior Vice President and R&D Head for Neuroscience, Ophthalmology and Rare Diseases at Hoffman La Roche. Earlier, he was Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas, including immunology, neuroscience, rare diseases, fibrosis and virology.

Dr. Keswani is an elected Fellow of the Royal College of Physicians, United Kingdom, and a former Neurology Faculty member at The Johns Hopkins Hospital, where he cared for patients with diverse neurological conditions and ran an RO1-funded Neuroimmunology research laboratory, focused on discovering treatments for neurodegeneration. He completed his residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at The Johns Hopkins Hospital.

During her tenure, Dr. Roberts led indication expansion efforts for INGREZZA® (valbenazine) capsules and the crinecerfont development program that led to US Food and Drug Administration approval of CRENESSITY™ (crinecerfont). She also was responsible for the recent successful Phase 2 proof of concept studies for osavampator and NBI-1117568, both of which are moving into registrational programs this year.